Details

Autor(en) / Beteiligte

• Houser, Katherine V.
• Chen, Grace L.
• Carter, Cristina
• Crank, Michelle C.
• Nguyen, Thuy A.
• Burgos Florez, Maria Claudia
• Berkowitz, Nina M.
• Mendoza, Floreliz
• Hendel, Cynthia Starr
• Gordon, Ingelise J.
• Coates, Emily E.
• Vazquez, Sandra
• Stein, Judy
• Case, Christopher L.
• Lawlor, Heather
• Carlton, Kevin
• Gaudinski, Martin R.
• Strom, Larisa
• Hofstetter, Amelia R.
• Liang, C. Jason
• Narpala, Sandeep
• Hatcher, Christian
• Gillespie, Rebecca A.
• Creanga, Adrian
• Kanekiyo, Masaru
• Raab, Julie E.
• Andrews, Sarah F.
• Zhang, Yi
• Yang, Eun Sung
• Wang, Lingshu
• Leung, Kwanyee
• Kong, Wing-Pui
• Freyn, Alec W.
• Nachbagauer, Raffael
• Palese, Peter
• Bailer, Robert T.
• McDermott, Adrian B.
• Koup, Richard A.
• Gall, Jason G.
• Arnold, Frank
• Mascola, John R.
• Graham, Barney S.
• Ledgerwood, Julie E.

Titel

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

Ist Teil von

• Nature medicine, 2022-02, Vol.28 (2), p.383-391

Ort / Verlag

New York: Nature Publishing Group US

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Currently, licensed seasonal influenza vaccines display variable vaccine effectiveness, and there remains a need for novel vaccine platforms capable of inducing broader responses against viral protein domains conserved among influenza subtypes. We conducted a first-in-human, randomized, open-label, phase 1 clinical trial ( NCT03186781 ) to evaluate a novel ferritin (H2HA-Ferritin) nanoparticle influenza vaccine platform. The H2 subtype has not circulated in humans since 1968. Adults born after 1968 have been exposed to only the H1 subtype of group 1 influenza viruses, which shares a conserved stem with H2. Including both H2-naive and H2-exposed adults in the trial allowed us to evaluate memory responses against the conserved stem domain in the presence or absence of pre-existing responses against the immunodominant HA head domain. Fifty healthy participants 18–70 years of age received H2HA-Ferritin intramuscularly as a single 20-μg dose ( n  = 5) or a 60-μg dose either twice in a homologous ( n  = 25) prime-boost regimen or once in a heterologous ( n  = 20) prime-boost regimen after a matched H2 DNA vaccine prime. The primary objective of this trial was to evaluate the safety and tolerability of H2HA-Ferritin either alone or in prime-boost regimens. The secondary objective was to evaluate antibody responses after vaccination. Both vaccines were safe and well tolerated, with the most common solicited symptom being mild headache after both H2HA-Ferritin ( n  = 15, 22%) and H2 DNA ( n  = 5, 25%). Exploratory analyses identified neutralizing antibody responses elicited by the H2HA-Ferritin vaccine in both H2-naive and H2-exposed populations. Furthermore, broadly neutralizing antibody responses against group 1 influenza viruses, including both seasonal H1 and avian H5 subtypes, were induced in the H2-naive population through targeting the HA stem. This ferritin nanoparticle vaccine technology represents a novel, safe and immunogenic platform with potential application for pandemic preparedness and universal influenza vaccine development. First-in-human trial of a self-assembling, ferritin nanoparticle-based influenza vaccine shows evidence that this new platform can elicit neutralizing and cross-reactive antibodies and has potential for further vaccine development.